| Similar Articles |
|---|
 |
The Motley Fool
June 22, 2011
Brian Orelli |
Building on Pfizer's Blockbuster New data for an expanded indication for Lyrica.   |
The Motley Fool
January 3, 2011
Brian Orelli |
Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
July 6, 2007
Brian Orelli |
Pain-Free Phase 2 Data Anesiva's pain medication is moving up the clinical trial ladder. The Adlea results are very promising, but investors should look at the state of the entire company before investing. |
The Motley Fool
November 6, 2006
Brian Lawler |
Neurocrine's Big Headache Another clinical trial means a steep drop in share price, but the biopharmaceutical's not dead yet. Investors, take note. |
The Motley Fool
October 8, 2007
Charly Travers |
Scanning 4 Biotechs There are major events set for the following biotech companies during this quarter. Investors, take note: BioMarin Pharmaceutical... Exelixis... Neurocrine Biosciences... Pain Therapeutics... |
The Motley Fool
March 29, 2010
Brian Orelli |
Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data. |
The Motley Fool
September 14, 2010
Luke Timmerman |
Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug. |
The Motley Fool
March 4, 2010
Brian Orelli |
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. |
The Motley Fool
November 4, 2005
Stephen D. Simpson |
A $99 Biotech Portfolio Can this biotech six-pack pay off for aggressive investors? Acadia Pharmaceuticals... Alexion Pharmaceuticals... Arena Pharmaceuticals... Crucell NV... DOV Pharmaceutical... Millennium Pharmaceuticals... |
The Motley Fool
March 25, 2011
Brian Orelli |
Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science. |
The Motley Fool
August 30, 2010
Brian Orelli |
Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help. |
The Motley Fool
August 31, 2009
Brian Orelli |
Don't Let Dummy Pills Make You a Dummy Investor Instead of being scared that the sugar pill will perform better than expected, pharma investors should factor it in and require more information before investing in companies with drugs that may be affected by it.. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
September 5, 2006
Brian Lawler |
Neurocrine Wakes Up Indiplon The biotech company announces new drug delays. Investors, take note. |
The Motley Fool
May 16, 2006
Stephen D. Simpson |
The FDA Tries to Put Neurocrine to Sleep A surprisingly worded rejection sends two stocks skidding. But setbacks aren't always terminal. While it won't be easy, Neurocrine Biosciences and DOV Pharmaceuticals investors may just want to hang on. |
The Motley Fool
June 15, 2007
Brian Lawler |
Neurocrine Moves Ahead Neurocrine resubmits a marketing application for its lead drug. Investors, take note. |
Wired
August 24, 2009
Steve Silberman |
Placebos Are Getting More Effective. Drugmakers Are Desperate to Know Why. The fact that taking a faux drug can powerfully improve some people's health -- the so-called placebo effect -- has long been considered an embarrassment to the serious practice of pharmacology. |
The Motley Fool
January 26, 2005
Stephen D. Simpson |
The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities. |
The Motley Fool
June 23, 2010
Kris Eddy |
Drugmakers Finally Recognize the Next Big Opportunity Drug companies seem to be increasing efforts to address female health problems. |
The Motley Fool
June 18, 2010
Denise Gellene |
San Diego's Neurocrine Biosciences Scores Second Big Deal in Two Days The San Diego biotech agreed to grant German drug maker Boehringer Ingelheim and signed a pact with Abbott Labs. |
The Motley Fool
August 1, 2007
Brian Lawler |
Neurocrine Awaits Its Destiny Neurocrine Biosciences updates investors on its plans for the rest of the year. A new marketing application was submitted for lead drug indiplon, following a negative FDA decision last year. Good news could come as soon as December 2007. |
The Motley Fool
January 24, 2007
Brian Lawler |
Neurocrine in the Green 2006 wasn't kind to the drug developer, but whatever happens with indiplon, Neurocrine's management deserves kudos for keeping investors well informed on the status of the drug and where the company stands as far as timelines go. |
The Motley Fool
December 14, 2007
Brian Lawler |
FDA Knocks Neurocrine a Knuckle Sandwich The FDA clobbers drugmaker Neurocrine with another delay. |
The Motley Fool
October 20, 2010
Matt Koppenheffer |
Neurocrine Biosciences Shares Popped: What You Need to Know Shares of biotech Neurocrine Biosciences were up more than 10% in intraday trading on higher-than-average volume. |
The Motley Fool
June 23, 2006
Stephen D. Simpson |
Neurocrine Biosciences: From Bad to Worse Pfizer's departure is a serious, though not fatal, blow to the biotech. While this story may yet have a happy ending, there's going to be a lot of nervous waiting between now and then. Investors, take note. |
Managed Care
October 2003
Martin Sipkoff |
Pain Management: Health Plans Need to Take Control Insurers have not focused much on chronic pain. They should. It presents a humanitarian and business opportunity. |
The Motley Fool
July 18, 2006
Brian Lawler |
Neurocrine's Tale of Woe After a couple of tough months, Neurocrine released its second-quarter results. This may be a great stock to own -- if you have the stomach to tolerate the risk. |
The Motley Fool
February 6, 2008
Brian Lawler |
Neurocrine on the Upswing? Neurocrine Bioscience releases year-end numbers, and updates investors on the status of its top drugs. |
The Motley Fool
May 8, 2007
Brian Lawler |
Neurocrine Is Waking Up After being put to sleep for much of 2006 following an unexpected FDA smackdown on its lead drug, indiplon, shares of the biopharma have boosted over 50% higher versus its lows last year. |
